Pfizer (NYSE:PFE) Price Target Raised to $36.00 at Guggenheim

Pfizer (NYSE:PFE) had its price objective boosted by Guggenheim from $35.00 to $36.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. Barclays started coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. HSBC increased their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Wolfe Research set a $24.00 price target on Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.19.

Pfizer Stock Performance

NYSE:PFE opened at $26.98 on Tuesday. The stock has a market cap of $153.39 billion, a P/E ratio of 19.83 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The business’s 50-day moving average price is $26.75 and its two-hundred day moving average price is $25.64. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.63 earnings per share. As a group, equities analysts predict that Pfizer will post 2.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of PFE. Horizon Financial Services LLC lifted its position in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. YANKCOM Partnership bought a new position in shares of Pfizer in the fourth quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer in the third quarter worth $29,000. Finally, HFM Investment Advisors LLC raised its holdings in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst upgrade/price-target bump: Guggenheim raised its Pfizer price target to $36 and holds a Buy rating, backing upside tied to key pipeline readouts and boosting sentiment among growth/pipeline-focused investors. Guggenheim price target report
• Positive Sentiment: Pipeline upside — prostate cancer and oncology momentum: Several analysts highlight potential high-value outcomes from an ongoing prostate-cancer trial and broader oncology progress, suggesting binary upside that could re-rate the stock if positive. Analyst bullish case on prostate cancer trial
• Neutral Sentiment: Management investor access — Q1 webcast scheduled for May 5: Pfizer invited the public to view a May 5 analyst call tied to its First Quarter 2026 Performance Report; that scheduled update creates a clear near-term catalyst for guidance or pipeline commentary. May 5 webcast invitation
• Neutral Sentiment: Management highlights oncology milestones: CFO Dave Denton discussed recent oncology progress on NYSE Live, reinforcing management’s message that non-COVID franchises and oncology are growth pillars. This supports a constructive narrative but is not immediately revenue-producing. CFO oncology interview
• Negative Sentiment: Lyme vaccine trial—strong efficacy but missed primary endpoint: Pfizer and partner Valneva reported >70% efficacy, yet the trial missed its pre-specified primary endpoint because fewer cases occurred than expected. That creates regulatory and execution uncertainty; Valneva’s shares plunged, underscoring market concern about read-across risk. Pfizer will pursue regulatory filings, but approval risk and timing remain uncertain. Lyme vaccine efficacy and trial miss

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.